Press releases

2020  |  2019  |  2018  |  All
March 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137
February 28, 2020
Compass Therapeutics to Present at the 40th Cowen Health Care Conference
January 6, 2020
Compass Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Presentations and publications

View all
March 12, 2020 | JCI Insight
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30

In the news

View all
April 6, 2020
Compass Therapeutics’ immuno-oncology prospect clears solid tumors in mice
December 11, 2019
Nature Reviews Drug Discovery: Immune agonist antibodies face critical test
December 4, 2019
BioWorld -Two’s companies: Crowd in bispecifics still growing as methodology sorted

Events

ASCO Annual Meeting
May 29 – June 2
Chicago, Illinois
BIO Digital
June 8 – 12
online
Raymond James Healthcare Conference
June 16 – 17
New York, NY
CICON
September 14 – 17
New York, NY
PEGS Europe
November 9 – 13
Lisbon, Portugal
SITC
November 10 – 15
National Harbor, MD
Stifel Healthcare Conference
November 17 – 18
New York, NY
Piper Sandler 32nd Annual Healthcare Conference
December 1 – 3
New York, NY
ASH
December 5 – 8
San Diego, CA